Rahul Sarugaser has joined Raymond James’ Canadian equity research team as managing director, equity analyst, healthcare, biotechnology & cannabis.
Most recently, Mr. Sarugaser was an equities research analyst at Paradigm Capital, where he also covered the biotechnology, healthcare, and cannabis sectors. His prior roles include director of business development at the Centre for Commercialization of Regenerative Medicine, investment manager with the Toronto-based MaRS Investment Accelerator Fund, and strategic marketing analyst at GE Healthcare.
“Rahul brings a combination of extensive medical sector expertise and financial analysis into this important role,” Daryl Swetlishoff, head of research at Raymond James, said in a statement.
“Our focus will be on covering Canadian growth-oriented firms pursuing enhanced medical solutions in the biotechnology, healthcare, wellness, medical devices, and cannabis fields,” he added.
